Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Biogen Inc (BIIB) vs JD.Com Inc (JD) Price & Performance

Biogen IncTrade
JD.Com IncTrade

Price performance (Past 24H)

Key statistics

Biogen Inc vs JD.Com Inc — how do they compare? Biogen Inc trades at $205.81 (market cap $30.13B), while JD.Com Inc trades at $31.16 (market cap $44.04B). The key difference: JD.Com Inc is the larger of the two by market cap, and JD.Com Inc pays a 3.13% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.

BIIBJD
Market Cap
$30.13B$44.04B
Sector
HealthConsumer Cyclical
52-Week High
$216.63$36.17
52-Week Low
$128.93$25.19
Enterprise Value
$37.20B$30.10B
Dividend Yield
3.13%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Biogen Inc

Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.

The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.

JD.Com Inc

JD.com trades at $33.47, up 1.52% today, with a bullish technical setup as price consolidates near recent highs. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.74 versus $0.57 expected, while revenue reached $1.31 trillion in 2025. Analyst consensus remains strongly positive with a $38.00 price target, though regulatory scrutiny from EU authorities over the Ceconomy acquisition presents a near-term headwind.

JD offers attractive valuation with a P/S of 0.24 and consistent earnings beats, but faces margin pressure and regulatory risks. Upside potential exists if Q2 2026 results meet high expectations, but investors must weigh competitive pressures in e-commerce and macroeconomic challenges affecting Chinese equities.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Read more on BIIB

About JD.Com Inc

JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.

Read more on JD